212 related articles for article (PubMed ID: 25321192)
1. Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies.
Chaudhary P; Thamake SI; Shetty P; Vishwanatha JK
Br J Cancer; 2014 Dec; 111(12):2328-41. PubMed ID: 25321192
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.
Shetty PK; Thamake SI; Biswas S; Johansson SL; Vishwanatha JK
PLoS One; 2012; 7(9):e44299. PubMed ID: 22957061
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer.
Zheng L; Foley K; Huang L; Leubner A; Mo G; Olino K; Edil BH; Mizuma M; Sharma R; Le DT; Anders RA; Illei PB; Van Eyk JE; Maitra A; Laheru D; Jaffee EM
PLoS One; 2011 Apr; 6(4):e19390. PubMed ID: 21572519
[TBL] [Abstract][Full Text] [Related]
4. Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.
Fan Y; Si W; Ji W; Wang Z; Gao Z; Tian R; Song W; Zhang H; Niu R; Zhang F
Breast Cancer Res; 2019 May; 21(1):66. PubMed ID: 31113450
[TBL] [Abstract][Full Text] [Related]
5. MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression.
Kpetemey M; Dasgupta S; Rajendiran S; Das S; Gibbs LD; Shetty P; Gryczynski Z; Vishwanatha JK
Mol Cancer; 2015 Aug; 14():156. PubMed ID: 26272794
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
7. ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer.
Zhang Y; Bi J; Zhu H; Shi M; Zeng X
Biosci Biotechnol Biochem; 2018 Oct; 82(10):1733-1741. PubMed ID: 29912633
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
9. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
10. Important role of annexin A2 (ANXA2) in new blood vessel development in vivo and human triple negative breast cancer (TNBC) growth.
Sharma MC; Jain D
Exp Mol Pathol; 2020 Oct; 116():104523. PubMed ID: 32866522
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
12. Cell surface interaction of annexin A2 and galectin-3 modulates epidermal growth factor receptor signaling in Her-2 negative breast cancer cells.
Shetty P; Bargale A; Patil BR; Mohan R; Dinesh US; Vishwanatha JK; Gai PB; Patil VS; Amsavardani TS
Mol Cell Biochem; 2016 Jan; 411(1-2):221-33. PubMed ID: 26438086
[TBL] [Abstract][Full Text] [Related]
13. Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
Wang Y; Deng J; Guo G; Tong A; Peng X; Chen H; Xu J; Liu Y; You C; Zhou L
J Neurooncol; 2017 Jan; 131(1):21-29. PubMed ID: 27640198
[TBL] [Abstract][Full Text] [Related]
14. ANXA2 (annexin A2) is crucial to ATG7-mediated autophagy, leading to tumor aggressiveness in triple-negative breast cancer cells.
Koh M; Lim H; Jin H; Kim M; Hong Y; Hwang YK; Woo Y; Kim ES; Kim SY; Kim KM; Lim HK; Jung J; Kang S; Park B; Lee HB; Han W; Lee MS; Moon A
Autophagy; 2024 Mar; 20(3):659-674. PubMed ID: 38290972
[TBL] [Abstract][Full Text] [Related]
15. CCL18 promotes the invasion and metastasis of breast cancer through Annexin A2.
Zhao C; Zheng S; Yan Z; Deng Z; Wang R; Zhang B
Oncol Rep; 2020 Feb; 43(2):571-580. PubMed ID: 31894281
[TBL] [Abstract][Full Text] [Related]
16. Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells.
Wang T; Yuan J; Zhang J; Tian R; Ji W; Zhou Y; Yang Y; Song W; Zhang F; Niu R
Oncotarget; 2015 Oct; 6(31):30975-92. PubMed ID: 26307676
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells.
Wu B; Zhang F; Yu M; Zhao P; Ji W; Zhang H; Han J; Niu R
Cell Prolif; 2012 Jun; 45(3):189-98. PubMed ID: 22452352
[TBL] [Abstract][Full Text] [Related]
18. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer.
Yotsumoto F; Oki E; Tokunaga E; Maehara Y; Kuroki M; Miyamoto S
Int J Cancer; 2010 Dec; 127(11):2707-17. PubMed ID: 20499311
[TBL] [Abstract][Full Text] [Related]
19. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
20. Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.
Li X; Duan Y; Qiao C; Zhou T; Yu M; Geng J; Feng J; Shen B; Lv M; Li Y
Technol Cancer Res Treat; 2016 Aug; 15(4):573-82. PubMed ID: 26041400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
